How it worksSafetyHealth libraryOur mission Sign in Start a free consult
Pymander
Free consult

Epclusa: what it treats, how to take it, side effects

Updated Sep 3, 20264 min readMedication
On this pageShort answer What does it treat? How do you take it? Side effects to know Who should not take it? When is it an emergency? What a Pymander AI doctor consult looks like Common questions Sources Related questions
Short answer

Epclusa combines sofosbuvir and velpatasvir in one daily tablet that treats all six hepatitis C genotypes, and for most patients it is a 12-week cure for a virus that used to be a life sentence.

The word "cure" here is real but precise: in the trials behind the approval, the overwhelming majority of patients had no detectable virus 12 weeks after finishing (the endpoint called SVR12, which counts as cure), with results varying by genotype, cirrhosis, and prior treatment.

Questions about epclusa? Ask our AI doctor - a straight answer in plain language, free, 24/7. Start a free consult Free · Private · 24/7

What does it treat?

Chronic hepatitis C, genotypes 1 through 6, in adults and children 3 and older. Patients without cirrhosis or with compensated cirrhosis take Epclusa alone for 12 weeks; decompensated cirrhosis adds ribavirin. Being pangenotypic, it skips the genotype-testing bottleneck that older regimens required, which is why it became the most prescribed hepatitis C regimen.

How do you take it?

One tablet once daily, with or without food, at the same time every day, for 12 weeks, and the full 12 weeks matter: stopping early is how a nearly-cured infection relapses. Acid reducers interfere: antacids go 4 hours apart, and H2 blockers and PPIs have timing rules to review with your pharmacist. Missed dose: take it when remembered the same day; never double up. Blood tests during treatment and at 12 weeks after finishing deliver the verdict.

Questions about EpclusaStart a free AI doctor consult

Side effects to know

Common: headache and fatigue, both usually mild; with ribavirin added, anemia, nausea, and insomnia join the list.

Serious: the boxed warning: hepatitis B can reactivate during hepatitis C treatment in coinfected patients, so everyone gets screened for HBV before starting. And a dangerous interaction: sofosbuvir with the heart drug amiodarone has caused severe, symptomatic slow heart rate, so that combination needs specialist management or an alternative.

Who should not take it?

The contraindications mostly live in the ribavirin add-on (pregnancy, for both partners, among them) and in interactions: strong inducers like rifampin, carbamazepine, and St. John's wort can crater the drug's levels and are incompatible. Severe kidney disease is specialist territory. Amiodarone patients need a cardiology-pharmacy huddle before starting.

When is it an emergency?

In an emergency, call 911

Call 911 for fainting, severe dizziness with a slow pulse, yellowing eyes or skin with dark urine (possible hepatitis B reactivation or liver trouble), or a severe allergic reaction. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.

How our AI doctor decides when to send you to care ›

What a Pymander AI doctor consult looks like

Do you know your genotype and whether you have cirrhosis, and what medications are you currently taking, all of them?
Genotype 3, no cirrhosis per the ultrasound. Just a statin and omeprazole for reflux.
Thanks for giving me all this information. Based on what you've said, genotype 3 without cirrhosis is squarely in Epclusa's 12-week sweet spot, and your med list raises the one interaction that matters: the omeprazole. Acid suppression lowers velpatasvir absorption, so the timing rules (or a re-think of the PPI) get sorted with the pharmacist before day one. Twelve tablets a week for twelve weeks, then the blood test that says the word you are hoping for. Here's your care note to share with your care team.
Care noteHCV genotype 3, starting curative therapyGT3, no cirrhosis, on statin + omeprazole. PPI timing flagged before Epclusa start; 12-week course and SVR12 testing schedule explained.View care note →
Illustrative example, not a real member's messages.

Common questions

Does it actually cure hepatitis C?

Yes, with precision: "cure" means no detectable virus 12 weeks after treatment ends (SVR12), and in the approval trials the overwhelming majority of patients across all six genotypes reached it. The honest caveats: results vary with genotype, cirrhosis, prior failed treatment, and adherence, and cure does not undo established cirrhosis damage or prevent reinfection.

Why do I need a hepatitis B test first?

The boxed warning. Treating hepatitis C can let a sleeping hepatitis B infection reactivate, sometimes severely. Every patient is screened for HBV before starting; if you carry it, treatment is coordinated with HBV management, not cancelled, but never skipped either.

Why do my acid pills matter so much?

Velpatasvir needs stomach acid to absorb. Antacids within 4 hours, H2 blockers like famotidine, and PPIs like omeprazole all reduce its levels, and reduced levels risk treatment failure. The rules are specific (PPI timing and dose caps, or switching strategies) and worth a pharmacist consult before the first dose.

What if I miss a few doses?

Same-day memory: take it when you remember, never double up. The bigger truth is that this is a 12-week course where adherence directly moves the cure probability, because gaps let the virus rebound. Daily alarms and a pillbox are not overkill for three months; they are the whole game.

Can the virus come back after I am cured?

Relapse (the same infection returning) happens in a small minority, mostly in the first 12 weeks, which is exactly what the SVR12 test checks. Reinfection is different: cure gives no immunity, so new exposure can start a new infection. Needle-sharing and other exposure routes remain off-limits after cure.

Is it true the treatment used to be a nightmare?

Yes. Interferon-era hepatitis C treatment meant injections for 6 to 12 months, flu-like misery, depression, and cure rates that hovered near half for common genotypes. The direct-acting antivirals starting in 2013 turned it into 8 to 12 weeks of a daily pill with mild side effects and cure as the expectation. Epclusa is that revolution's most-used product.

Questions about this?Start a free consult